MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification

Journal of Pathology

Volumn 198, Issue 4, 2002, Pages 495-501

  Valent, Alexander ^a   Le Roux, Gwenaëlle ^a   Barrois, Michel ^a   Terrier Lacombe, Marie Jose ^a   Valteau Couanet, Dominique ^a   Léon, Bernadette ^a   Spengler, Barbara ^b   Lenoir, Gilbert ^a   Bénard, Jean ^a   Bernheim, Alain ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b FORDHAM UNIVERSITY   (United States)

Author keywords

FISH; MYCN gain; MYCN overrexpression; Neuroblastoma; Unbalanced translocation

Indexed keywords

ONCOPROTEIN; PROTEIN MYCN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INVASION; CHROMOSOME 2; CHROMOSOME 2P; CHROMOSOME PAIRING; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DISEASE COURSE; EXPERIMENTAL MODEL; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE INSERTION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; HYPOTHESIS; MAJOR CLINICAL STUDY; NEUROBLASTOMA; NEUROBLASTOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTO ONCOGENE; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CHROMOSOMES, HUMAN, PAIR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; NEOPLASM PROTEINS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PLOIDIES; POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; UP-REGULATION;

EID: 0036901432     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1244     Document Type: Article

References (34)

1. Evans AE, D'Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. Children's cancer study group A. Cancer 1971; 27: 374-378.
2. Evans AE, D'Angio GJ, Propert K, Anderson J, Hann HW. Prognostic factors in neuroblastoma. Cancer 1987; 59: 1853-1859.
3. Brodeur GM. Molecular basis of heterogeneity in human neuroblastoma. Eur J Cancer 1995; 31A: 505-510.
4. Schwab M, Alitalo K, Klempnauer KH, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumor. Nature 1983; 305: 245-248.
5. Schwab M, Varmus ME, Bishop JM, et al. Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature 1984; 308: 288-291.
6. Look AT, Hayes HA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group Study. J Clin Oncol 1991; 9: 581-591.
7. Ambros PF, Ambros IM. Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 2001; 37: 492-504.
8. Rubie H, Hartmann O, Michon J, et al. N-myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL90 study. J Clin Oncol 1997; 15: 1171-1182.
9. Schwab M. MYCN amplification in neuroblastoma. In Neuroblastoma, Brodeur GM, Sawada T, Tsuchida Y, Voute PA (eds). Elsevier: Amsterdam, 2000; 75-83.
10. Corvi R, Savelyeva L, Schwab M. Duplication of N-myc at its resident site 2p24 may be a mechanism of activation alternative to amplification in human neuroblastoma cells. Cancer Res 1995; 55: 3471-3474.
11. Van Roy N, Van Limbergen H, Vandesompele J, et al. Chromosome 2 short arm translocation revealed by M-FISH analysis of neuroblastoma cell lines. Med Pediatr Oncol 2000; 35: 538-540.
12. Valent A, Bénard J, Clausse B, et al. In vivo elimination of acentric double minutes containing amplified MYCN from neuroblastoma tumor cells through the formation of micronuclei. Am J Pathol 2001; 158: 1579-1584.
13. Valent A, Bénard J, Da Silva J, et al. Phenotypic and genotypic diversity of human neuroblastoma studied in 3 IGR cell line models derived from bone marrow metastasis. Cancer Genet Cytogenet 1999; 112: 124-129.
14. Vindelov L, Christensen I, Nissen N. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983; 3: 323-327.
15. Bourhis J, De Vathaire F, Wilson G, et al. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res 1991; 51: 33-36.
16. Schwab M. Oncogene amplification in solid tumors. Cancer Biol 1999; 9: 319-325.
17. Plantaz D, Vandesompele J, Van Roy N, et al. CGH analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer 2001; 91: 680-686.
18. Maris JM, White PS, Beltinger CP, et al. Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 1995; 55: 4664-4669.
19. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996; 97: 362-364.
20. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999; 340: 1954-1961.
21. Brinkschmidt C, Christiansen H, Terpe HJ, et al. Distal chromosome 17 gains in neuroblastoma detected by CGH are associated with a poor clinical outcome. Med Pediatr Oncol 2001; 36: 11-13.
22. Bown N, Lastowska M, Cotterill S, et al. 17q gain in neuroblastoma predicts adverse clinical outcome. Med Pediatr Oncol 2001; 36: 14-19.
23. Cohn S, Ikegaki N. Expression of MYCN mRNA and protein. In Neuroblastoma, Brodeur GM, Sawada T, Tsuchida Y, Voute PA (eds). Elsevier: Amsterdam, 2000; 137-146.
24. Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 1992; 52: 1364-1368.
25. Bordow SB, Norris MD, Haber PS, Marshall GM, Haber M. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J Clin Oncol 1998; 16: 3286-3294.
26. Chan HS, Gallie BL, DeBoer G, Haddad G, Ikegaki N, Dimitroulakos J. MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res 1997; 3: 1699-1706.
27. Cohn S, London WB, Huang D, et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol 2000; 18: 3604-3613.
28. Peace BE, Livingston G, Silberstein EB, Loper JC. A case of elevated spontaneous micronucleus frequency derived from chromosome 2. Mut Res 1999; 430: 109-119.
29. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastoma. N Engl J Med 1985; 313: 1111-1116.
30. Nakagawara A, Ikeda K, Tsuda T, Higashi K. N-myc oncogene amplification and prognostic factors of neuroblastoma in children. J Pediatr Surg 1987; 22: 895-898.
31. Kaneko M, Nishihira H, Mugishima M, et al. Stratification of treatment of stage 4 neuroblastoma patients based on N-myc amplification status. Med Pediatr Oncol 1998; 31: 1-7.
32. Suita S, Tajiri T, Sera Y, et al. Improved survival for patients with advanced neuroblastoma after high-dose combined chemotherapy based in part on N-myc amplification. J Pediatr Surg 2000; 35: 1737-1741.
33. Lutz W, Fulda S, Jeremias I, Debatin KM, Schwab M. MYCN and IFNγ cooperate in apoptosis of human neuroblastoma cells. Oncogene 1998; 17: 339-346.
34. Fulda S, Lutz W, Schwab M, Debatin KM. MYCN sensitizes neuroblastoma cells for drug-triggered apoptosis. Med Pediatr Oncol 2000; 35: 582-584.